DSP Small Cap Fund
DSP Mutual FundEquity: Small CapRegular planGrowth
Overview
NAV
₹223.0360
Gain 0.34% 1-day changeData as of 9 Oct 2026
- 1 year
- Gain 15.8%
- 3 years
- Gain 15.7%
- 5 years
- Gain 15.1%
The principal will be at Very High risk
Data as of 9 Oct 2026Source: amfiHow we calculatePast performance may or may not be sustained in future. Returns shown are not an indication of future returns.
Trailing returns
Periods under 1 year show absolute return. 1 year and longer show CAGR (annualised).
| Period | This fund | Nifty Smallcap 250 TRI | Category average |
|---|---|---|---|
| 1 month | Loss 4.04% | Loss 4.62% | Loss 4.17% |
| 3 months | Gain 1.20% | Loss 1.40% | Gain 0.53% |
| 6 months | Gain 17.08% | Gain 13.80% | Gain 16.60% |
| 1 year | Gain 15.77% | Gain 3.93% | Gain 9.25% |
| 3 years | Gain 15.72% | Gain 13.85% | Gain 14.16% |
| 5 years | Gain 15.14% | Gain 13.44% | Gain 13.49% |
| 7 years | Gain 23.95% | Gain 22.36% | Gain 22.95% |
| 10 years | Gain 15.49% | Gain 14.05% | Gain 15.65% |
| Since launch | Gain 17.42% | Gain 15.54% | Gain 16.64% |
SIP returns (XIRR)
XIRR of a monthly SIP over each period, valued at the latest NAV.
| Period | This fund | Nifty Smallcap 250 TRI | Category average |
|---|---|---|---|
| 1 year | Gain 19.75% | Gain 9.47% | Gain 15.22% |
| 3 years | Gain 12.88% | Gain 6.70% | Gain 9.13% |
| 5 years | Gain 16.31% | Gain 13.89% | Gain 14.11% |
| 10 years | Gain 18.52% | Gain 16.77% | Gain 17.69% |
Calendar-year returns
Show as table
| Year | This fund | Nifty Smallcap 250 TRI |
|---|---|---|
| 2026 (year to date) | ▲ +14.03% | ▲ +5.85% |
| 2025 | ▼ −2.79% | ▼ −5.48% |
| 2024 | ▲ +25.60% | ▲ +27.21% |
| 2023 | ▲ +41.21% | ▲ +49.09% |
| 2022 | ▲ +0.46% | ▼ −2.64% |
| 2021 | ▲ +58.90% | ▲ +63.34% |
| 2020 | ▲ +33.12% | ▲ +26.46% |
| 2019 | ▲ +0.74% | ▼ −7.26% |
| 2018 | ▼ −25.45% | ▼ −26.15% |
| 2017 | ▲ +42.77% | ▲ +58.47% |
Past performance may or may not be sustained in future. Returns shown are not an indication of future returns.
Rolling returns
Returns over every possible holding period since launch show the range of outcomes an investor could have had, not just one start date.
| Holding period | 1Y | 3Y | 5Y |
|---|---|---|---|
| Lowest | −66.76% | −13.31% | −1.21% |
| Median | 14.59% | 21.82% | 21.05% |
| Average | 22.33% | 21.24% | 20.61% |
| Highest | 213.97% | 55.82% | 36.48% |
| Periods with a loss | 27.3% | 10.1% | 0.5% |
| Periods above 8% | 58.6% | 78.6% | 92.3% |
| Periods above 10% | 55.8% | 75.5% | 86.2% |
| Periods above 12% | 53.5% | 72.4% | 79.7% |
| Number of periods | 3972 | 3483 | 2991 |
Distribution and comparison with the benchmark
Calculating…
Past performance may or may not be sustained in future. Returns shown are not an indication of future returns.
Risk measures (3 years)
Calculated on daily NAVs over the last 3 years. Tap ? for a plain-language explanation.
- Standard deviation
Standard deviation
How much the fund's returns swing around their average, per year. A higher number means a bumpier ride.
- 17.01%
- Sharpe ratio
Sharpe ratio
Return earned above a treasury-bill rate for each unit of ups and downs. Higher means more return for the risk taken.
- 0.60
- Sortino ratio
Sortino ratio
Like the Sharpe ratio, but it counts only the falls, not the rises. Higher is better.
- 0.81
- Beta
Beta
How much the fund tends to move when its benchmark moves. 1 means the same as the benchmark; below 1 means it moved less.
- 0.84
- Alpha
Alpha
Return per year above what the fund's beta would predict from the benchmark. Positive means the fund added value.
- ▲ +2.72%
- Maximum drawdown
Maximum drawdown
The deepest fall from a peak to a later low. It shows the worst loss an investor would have seen on paper.
- ▼ −24.29%
- Up-market capture
Up-market capture
How much of the benchmark's gains the fund caught in rising months. Above 100% means it rose more.
- 98.1%
- Down-market capture
Down-market capture
How much of the benchmark's losses the fund took in falling months. Below 100% means it fell less.
- 88.0%
Beta, alpha and capture ratios are measured against Nifty Smallcap 250 TRI.
Fund facts
- Fund size (AUM)
- ₹20,905 Cr
- Expense ratio (TER)
- 1.72%
- Exit load
- Not available
- Minimum SIP
- ₹100
- Minimum lumpsum
- ₹1,000
- Launch date
- 4 May 2007
- Fund managers
- Vinit Sambre
- Benchmark index
- Nifty Smallcap 250 TRI
- Category
- Equity: Small Cap
- Fund house
- DSP Mutual Fund
- Scheme type
- Open Ended
- AMFI scheme code
- 105989
- ISIN
- INF740K01797
Investment objective
The primary investment objective is to seek to generate long term capital appreciation from a portfolio that is substantially constituted of equity and equity related securities of small cap companies/entities. From time to time, the fund manager will also seek participation in other equity and equity related instruments to achieve optimal portfolio construction.
Portfolio holdings
| Holding | Sector | Weight |
|---|---|---|
| TREPS / Reverse Repo Investments | — | 11.41% |
| Lumax Auto Technologies LimitedAuto Components | Auto Components | 5.16% |
| Kirloskar Oil Engines LimitedIndustrial Products | Industrial Products | 3.77% |
| Thangamayil Jewellery LimitedConsumer Durables | Consumer Durables | 3.37% |
| Welspun Corp LimitedIndustrial Products | Industrial Products | 2.94% |
| Sansera Engineering LimitedAuto Components | Auto Components | 2.85% |
| Spr Auto Technologies LimitedAuto Components | Auto Components | 2.34% |
| IPCA Laboratories LimitedPharmaceuticals & Biotechnology | Pharmaceuticals & Biotechnology | 2.14% |
| eClerx Services LimitedCommercial Services & Supplies | Commercial Services & Supplies | 2.02% |
| Dodla Dairy LimitedFood Products | Food Products | 1.96% |
| Jubilant Ingrevia LimitedChemicals & Petrochemicals | Chemicals & Petrochemicals | 1.83% |
| LT Foods LimitedAgricultural Food & Other Products | Agricultural Food & Other Products | 1.82% |
| Gland Pharma LimitedPharmaceuticals & Biotechnology | Pharmaceuticals & Biotechnology | 1.78% |
| Prudent Corporate Advisory Services LimitedCapital Markets | Capital Markets | 1.71% |
| Concord Biotech LimitedPharmaceuticals & Biotechnology | Pharmaceuticals & Biotechnology | 1.68% |
Portfolio as of 30 Sept 2026 · top 15 of 86 holdings, 46.8% of the portfolio
Try this fund in our tools
See how a SIP, a lumpsum or withdrawals in this fund would have done, using its real NAV history.
Data sources
| Data | Source | As of |
|---|---|---|
| Latest NAV | amfi | 9 Oct 2026 |
| NAV history | captnemo | 9 Oct 2026 |
| Expense ratio | amfi | 9 Oct 2026 |
| Fund size | amfi | 8 Oct 2026 |
| Fund managers | kuvera | 11 Oct 2026 |
| Riskometer | amfi | 8 Oct 2026 |
| Scheme details | amfi | 9 Oct 2026 |
| Holdings | amc:dsp | 30 Sept 2026 |
| Benchmark | niftyindices | 9 Oct 2026 |
| minSip | kuvera | 11 Oct 2026 |
| minLumpsum | amfi | 9 Oct 2026 |
| objective | kuvera | 11 Oct 2026 |
| launch | amfi | 9 Oct 2026 |
Mutual fund investments are subject to market risks, read all scheme related documents carefully.